Drug intelligence / Profile preview

ART-VAX

Development stage: Unknown
Lead developer: Merck Animal Health
Modality: Vaccines & Immunotherapeutics
Administration: Inhalation, Oral

Overview

ART-VAX is a live bacterial vaccine developed by Merck Animal Health for the immunization of healthy turkeys against rhinotracheitis, also known as turkey coryza, caused by *Bordetella avium*. The vaccine contains a chemically induced mutant strain of *Bordetella avium* that serves as a live-attenuated agent to stimulate a protective immune response. It is specifically designed for veterinary use and is administered to poults via spray at one day of age, followed by a booster administration in the drinking water at two weeks of age.

Brand names: ART-VAX

Beyond the preview

Go deeper on ART-VAX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ART-VAX.

Explore the full profile